MA35050B1 - Formulation d'otamixaban ayant une stabilité améliorée - Google Patents

Formulation d'otamixaban ayant une stabilité améliorée

Info

Publication number
MA35050B1
MA35050B1 MA36345A MA36345A MA35050B1 MA 35050 B1 MA35050 B1 MA 35050B1 MA 36345 A MA36345 A MA 36345A MA 36345 A MA36345 A MA 36345A MA 35050 B1 MA35050 B1 MA 35050B1
Authority
MA
Morocco
Prior art keywords
otamixaban
formulation
improved stability
oxidopyridin
imino
Prior art date
Application number
MA36345A
Other languages
English (en)
Inventor
Walter Kamm
Till Bussemer
Doris Andert
Bernd KÜHN
Ernst-Josef Todt
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA35050B1 publication Critical patent/MA35050B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une composition pharmaceutique comprenant du (2R,3R)-2-{3-[amino(imino)méthyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]
MA36345A 2011-03-29 2012-03-27 Formulation d'otamixaban ayant une stabilité améliorée MA35050B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11305347 2011-03-29
US201161499941P 2011-06-22 2011-06-22
PCT/EP2012/055361 WO2012130819A1 (fr) 2011-03-29 2012-03-27 Formulations d'otamixaban ayant une stabilité améliorée

Publications (1)

Publication Number Publication Date
MA35050B1 true MA35050B1 (fr) 2014-04-03

Family

ID=44584895

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36345A MA35050B1 (fr) 2011-03-29 2012-03-27 Formulation d'otamixaban ayant une stabilité améliorée

Country Status (19)

Country Link
US (3) US20120252852A1 (fr)
EP (1) EP2691075A1 (fr)
JP (1) JP5993933B2 (fr)
KR (1) KR101844623B1 (fr)
CN (1) CN103561723B (fr)
AR (1) AR085580A1 (fr)
AU (1) AU2012234323A1 (fr)
BR (1) BR112013024801A2 (fr)
CA (1) CA2830962C (fr)
CO (1) CO6801755A2 (fr)
EA (1) EA025572B1 (fr)
IL (1) IL228573A (fr)
MA (1) MA35050B1 (fr)
MX (1) MX342324B (fr)
PH (1) PH12013501991A1 (fr)
SG (1) SG193932A1 (fr)
UY (1) UY33975A (fr)
WO (1) WO2012130819A1 (fr)
ZA (1) ZA201308061B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2691075A1 (fr) 2011-03-29 2014-02-05 Sanofi Formulations d'otamixaban ayant une stabilité améliorée
KR102295748B1 (ko) 2013-01-31 2021-09-01 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 피리돈 아미드
DE102013212933B3 (de) * 2013-07-03 2014-11-27 Schaeffler Technologies Gmbh & Co. Kg Lageranordnung in einem Elektromotor
DK3668516T3 (da) 2017-08-16 2021-12-13 Merck Patent Gmbh Stabile lyofilisater omfattende 5,10-methylen-(6r)-tetrahydrofolsyre og en dicarboxylsyre
CN109010273B (zh) * 2018-10-08 2021-03-19 中国药科大学 一种阿哌沙班纳米混悬剂及其制备方法
CN113384526A (zh) * 2021-08-03 2021-09-14 合肥医工医药股份有限公司 一种稳定的阿哌沙班口服溶液制剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3030272A (en) * 1960-05-26 1962-04-17 Abbott Lab Stable heaparin solution
ES2224200T3 (es) 1992-11-27 2005-03-01 Mayne Pharma (Usa) Inc. Composicion inyectable estable de paclitaxel.
US6080767A (en) 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
DK0906094T3 (da) 1996-01-02 2003-10-20 Aventis Pharma Inc Substituerede N-[(aminoiminomethyl- eller aminomethyl)phenyl]propylamider
GB0108903D0 (en) * 2000-10-05 2001-05-30 Aventis Pharm Prod Inc Novel crystalline forms of a factor Xa inhibitor
US20050059719A1 (en) * 2003-09-16 2005-03-17 Badawy Sherif Ibrahim Farag Solid dosage formulation containing a Factor Xa inhibitor and method
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation
NZ597957A (en) * 2009-07-29 2014-05-30 Sanofi Sa Otamixaban for treatment of elderly and renal impaired non-st elevation myocardial infarction patients
EP2691075A1 (fr) 2011-03-29 2014-02-05 Sanofi Formulations d'otamixaban ayant une stabilité améliorée
ES2539236T3 (es) 2011-03-29 2015-06-29 Sanofi Sal de ácido benzoico de Otamixaban

Also Published As

Publication number Publication date
PH12013501991A1 (en) 2013-11-25
KR20140019818A (ko) 2014-02-17
KR101844623B1 (ko) 2018-04-02
US20140018398A1 (en) 2014-01-16
CO6801755A2 (es) 2013-11-29
SG193932A1 (en) 2013-11-29
US20170224668A1 (en) 2017-08-10
AR085580A1 (es) 2013-10-09
EA201391406A1 (ru) 2014-02-28
AU2012234323A1 (en) 2013-10-17
NZ616180A (en) 2015-10-30
MX342324B (es) 2016-09-23
US9993464B2 (en) 2018-06-12
CN103561723B (zh) 2016-04-20
EP2691075A1 (fr) 2014-02-05
JP5993933B2 (ja) 2016-09-14
US20120252852A1 (en) 2012-10-04
CN103561723A (zh) 2014-02-05
CA2830962C (fr) 2019-06-18
IL228573A0 (en) 2013-12-31
EA025572B1 (ru) 2017-01-30
UY33975A (es) 2012-10-31
IL228573A (en) 2017-12-31
BR112013024801A2 (pt) 2016-12-20
WO2012130819A1 (fr) 2012-10-04
CA2830962A1 (fr) 2012-10-04
JP2014509621A (ja) 2014-04-21
MX2013011260A (es) 2014-03-27
ZA201308061B (en) 2015-01-28

Similar Documents

Publication Publication Date Title
JO3187B1 (ar) (4-(8- ميثوكسي بروبان -2-يل)-2-(تترا هيدرو - 2h - بيران-4-يل)- 1h - ايميدازو [ 4, 5- c ] كوينولين -7-يل)-3, 5- داي ميثيل ايزوكسازول واستخدامه كمثبط نطاق برومو
MA35050B1 (fr) Formulation d'otamixaban ayant une stabilité améliorée
CY1121421T1 (el) Φαρμακοτεχνικες μορφες
IT1404931B1 (it) Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
IN2014DN08870A (fr)
MX351148B (es) Formulacion de anticuerpo beta amiloide.
EP2578209A4 (fr) Composition nanoparticulaire contenant des antibiotiques pour administration intramammaire, à usage animal
BR112012023382A2 (pt) compostos, composições e métodos de uso de imidazopiridina.
DOP2010000326A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
DK2718293T3 (da) Substituerede pyridopyraziner som hidtil ukendte syk-inhibitorer
EP2580206A4 (fr) Composition pharmaceutique comprenant un dérivé d'amide ou son sel pharmaceutiquement acceptable
MA34069B1 (fr) Dérivés de n-(imidazopyrimidin-7-yl)hétéroarylamide et leur utilisation comme inhibiteurs de pde10a)
EP2881384A8 (fr) Composé hétérocyclique contenant de l'azote partiellement saturé
WO2013004995A8 (fr) Composés pyrimidinones et leur utilisation
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
PH12014500809A1 (en) Polymorphs of arry-380, a slective herb2 inhibitor and pharmaceutical compositions containing them
BR112014025041B8 (pt) Composição farmacêutica
EP2672989A4 (fr) Composition immunogène comprenant des oligopeptides d'alpha-hémolysine
ME03750B (fr) Formulation pharmaceutique comprenant de l'inositol
EA201201082A1 (ru) Фармацевтическая композиция, содержащая n-(2-хлор-6-метилфенил)-2-[[6-[4-(2-гидроксиэтил)-1-пиперазинил]-2-метил-4-пиримидинил]амино]-5-тиазолкарбоксамид
MX2015007540A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
WO2012162439A3 (fr) Compositions comprenant de l'acide fusidique et leurs emballages
UA110979C2 (uk) Рідка фармацевтична композиція, яка включає нітизинон